Solopharm Defends Its Rights to «Trekrezan»: Courts of All Instances Uphold the Company’s Legal Position
Pharmaceutical company Solopharm (Nelovia LTD, the parent company of Grotex LLC) has completed a significant stage of litigation to protect its rights to the «Trekrezan» brand. Three judicial instances, including the Supreme Court of the Russian Federation, upheld the company’s claims. The decision of Rospatent dated June 24, 2024 (which had maintained legal protection of the «Trekresil» trademark) was declared unlawful.
Consistent Victories in Court
Solopharm’s legal position was confirmed in a series of judicial acts:
- On May 21, 2025, the Intellectual Property Court issued a decision invalidating Rospatent’s ruling of June 24, 2024, finding that it did not comply with paragraph 6 of Article 1483 of the Civil Code of the Russian Federation, and ordered the authority to re-examine the right holder’s objection.
In its decision, the court established that the designations «Trekrezan» and «Trekresil» (the latter registered at a later date) share «phonetic identity in their initial elements, which constitute the greater part of the designations and on which consumer attention is focused». The court also identified «graphic similarity resulting from the use of uppercase letters of the Russian alphabet in black color». Based on the foregoing, «the court concluded that the contested trademark bears a certain degree of similarity to each of the opposing trademarks».
- On September 25, 2025, the Presidium of the Intellectual Property Court upheld the decision of May 21, 2025 without modification.
- On January 19, 2026, a judge of the Supreme Court of the Russian Federation refused to refer the cassation appeals for consideration by the Judicial Panel for Economic Disputes.
The court decisions have entered into legal force. Solopharm’s legal position regarding the unlawfulness of Rospatent’s decision of June 24, 2024 has received final confirmation at the highest judicial level. Solopharm is participating in the renewed examination of its objection before Rospatent and continues to defend its rights to the «Trekrezan» brand.
Strategy for Protecting Innovation and Brands
Solopharm consistently invests in scientific research, original formulations, and clinical studies. The medicinal product «Trekrezan» is the result of many years of work by the company’s scientific teams, and the protection of intellectual property is a strategic priority for Solopharm.
The courts have emphasized that the use of similar trademarks creates a risk of misleading consumers and violates the principles of fair competition. The adopted decisions establish an important legal precedent for the pharmaceutical market and underscore the necessity of respecting innovations and brands.
Comment from the Solopharm Press Office
«Solopharm builds its business on innovation, scientific expertise, and ethical responsibility toward patients and the medical community. We consider it unacceptable to use designations that may mislead patients and healthcare professionals. The court decisions have confirmed our legal position and strengthened trust in the ‘Trekrezan’ brand. The company will continue to consistently protect its developments and uphold high standards of fair competition in the pharmaceutical industry», the Solopharm press office stated.
